Mackenzie Financial
XERS icon

Mackenzie Financial’s Xeris Biopharma Holdings XERS Stock Holding History

Mackenzie Financial’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-152,161
Closed -$1.24M – 1833
2025
Q3 		$1.24M Buy
152,161
+14,069
+10% +$93.5K ﹤0.01% 1002
2025
Q2 		$645K Sell
138,092
-4,012
-3% -$18.4K ﹤0.01% 1142
2025
Q1 		$780K Buy
142,104
+12,152
+9% +$49.1K ﹤0.01% 1047
2024
Q4 		$441K Buy
129,952
+106,153
+446% +$341K ﹤0.01% 1228
2024
Q3 		$67.8K Buy
+23,799
New +$61.1K ﹤0.01% 1517
2024
Q2 		– Sell
-35,375
Closed -$78.2K – 1642
2024
Q1 		$78.2K Buy
35,375
+9,397
+36% +$24.3K ﹤0.01% 1449
2023
Q4 		$61K Hold
25,978
– – ﹤0.01% 1434
2023
Q3 		$42.6K Hold
25,978
– – ﹤0.01% 1421
2023
Q2 		$66.2K Buy
+25,978
New +$66.1K ﹤0.01% 1436

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mackenzie Financial's XERS Position: Q4 2025 in Review

Mackenzie Financial sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 152,161 shares — an estimated $1.24M sold.

Mackenzie Financial first reported a position in XERS in Q2 2023 and held it in 9 quarters. The position peaked at $1.24M in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Mackenzie Financial reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Mackenzie Financial sold 152,161 Xeris Biopharma Holdings shares in Q4 2025, an estimated $1.24M.
  • Mackenzie Financial first reported a position in Xeris Biopharma Holdings in Q2 2023 and held it in 9 quarters.
  • Mackenzie Financial's Xeris Biopharma Holdings position peaked at $1.24M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Mackenzie Financial's 13F filing for Q4 2025, filed 18 Feb 2026.